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Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in breast and other cancers. However,
clinical utility of the immunohistochemical (IHC) assay for Ki67 immunohistochemistry has been hampered by unacceptable
between-laboratory analytical variability. The International Ki67 Working Group has conducted a series of studies aiming to
decrease this variability and improve the evaluation of Ki67. This study tries to assess whether acceptable performance can be
achieved on prestained core-cut biopsies using a standardized scoring method. Sections from 30 primary ER+ breast cancer core
biopsies were centrally stained for Ki67 and circulated among 22 laboratories in 11 countries. Each laboratory scored Ki67 using
three methods: (1) global (4 fields of 100 cells each); (2) weighted global (same as global but weighted by estimated percentages of
total area); and (3) hot-spot (single field of 500 cells). The intraclass correlation coefficient (ICC), a measure of interlaboratory
agreement, for the unweighted global method (0.87; 95% credible interval (CI): 0.81–0.93) met the prespecified success criterion for
scoring reproducibility, whereas that for the weighted global (0.87; 95% CI: 0.7999–0.93) and hot-spot methods (0.84; 95% CI: 0.77–
0.92) marginally failed to do so. The unweighted global assessment of Ki67 IHC analysis on core biopsies met the prespecified
criterion of success for scoring reproducibility. A few cases still showed large scoring discrepancies. Establishment of external
quality assessment schemes is likely to improve the agreement between laboratories further. Additional evaluations are needed to
assess staining variability and clinical validity in appropriate cohorts of samples.
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INTRODUCTION
Assessment of the nuclear proliferation biomarker Ki67 has
multiple potential roles in breast and other cancers,1,2 either in
standard clinical practice as a prognostic3–11 and predictive5,7,10,12
marker or in clinical trials as an eligibility criterion or as a primary
end point in early-phase neoadjuvant studies.10 Perhaps the most
critical use for standard clinical care would be to determine
prognosis in the context of other factors, such as nodal status,
tumor size, and estrogen receptor, progesterone receptor, and
HER2 status. Although gene expression multiparameter molecular
assays have gained widespread use in the United States and other
countries, these assays may not be an option in many
clinical settings owing to availability or economic considerations.
Therefore, the Ki67 immunohistochemistry assay might offer a
cost-effective alternative.13–15 The 2015 St Gallen consensus panel
stated that the majority of new breast cancer cases and breast
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cancer deaths now occur in less developed regions of the world,13
accentuating the need for low cost, widely accessible biomarkers.
However, despite extensive effort spent on evaluating Ki67 as a
prognostic and/or predictive marker in the past three decades,
this biomarker is still not completely integrated into clinical
decision making,16 due mainly to the lack of standardization in
staining techniques and scoring methods.3,10,16
The International Ki67 Working Group has undertaken a
systematic multiphase program to determine whether Ki67 scoring
can be analytically validated and standardized across labo-
ratories.10,17,18 In phase 1, variability in visual interpretation, as
assessed by the intraclass correlation coefficient (ICC) estimate of
interobserver reproducibility, was the most important source of
variability (ICC= 0.71, 95% credible interval (CI): 0.47–0.78).17 In
phase 2, substantial levels of agreement were achieved when the
various laboratories followed clearly defined, standardized training
exercise and scoring methods.18 Indeed, the interobserver varia-
bility observed in phase 2 (ICC= 0.94, 95% CI: 0.90–0.97) is similar to
the intraobserver reproducibility (ICC=0.94; 95% CI: 0.93–0.97)
observed in phase 1. However, this level of agreement was
achieved when scoring the same tumors on tissue microarrays,
whereas in clinical practice biomarker decisions are made on core-
cut biopsy or on surgical excision whole-section specimens. Such
specimens require pathologists to select specific regions for
assessment within a larger area, and so increased variability in
scoring would be expected.
Given the encouraging result achieved on breast cancer tissue
microarrays, we proceeded to phase 3 to assess whether
acceptable performance can be achieved on core-cut biopsies
using a similar, standardized method including two distinct
approaches in selecting which area to score.
RESULTS
Interlaboratory ICC concordance of Ki67 according to method of
scoring
The different-section ICC estimate for the unweighted global score
was 0.87 (95%CI: 0.81–0.93), and therefore met the prespecified
success criterion (lower bound of credible interval exceeding 0.8;
Table 1). The different-section ICCs for the weighted global score
and hot-spot score were 0.87 (95%CI: 0.7999–0.93) and 0.84 (95%
CI: 0.77–0.92), respectively, and therefore both methods had ICC
credible intervals that extended below the success criterion. The
corresponding same-section ICC estimates for the unweighted
global, weighted global and hot-spot scores were 0.88 (95% CI:
0.81–0.93), 0.87 (95% CI: 0.80–0.93) and 0.84 (95% CI: 0.77–0.92),
respectively. Figure 1 displays the side-by-side boxplots of Ki67
scores across laboratories by group. Summary statistics for the
Ki67 scores across the 22 laboratories are given in Supplementary
Tables 2.
Variance component analyses show that, regardless of scoring
method, biological variation among different patients was the
largest component of the total variation, indicating that the Ki67
score is reflecting inherent properties of the tumor and that the
effect on the score introduced by the immunohistochemistry assay
technical variation (sectioning, staining, and scoring) is relatively
small (Figure 2, Supplementary Table 5).
Interlaboratory variation of Ki67 scoring
Figure 3 displays the variation in scores across laboratories for
each case, in spaghetti plot format. Each line represents scores
from one laboratory. Figure 4 presents the scores in a heat map
format with the columns (laboratories) sorted (within each group)
by the median scores across cases and the rows (cases) sorted by
the median scores across laboratories.
Overall it can be seen that most laboratories show good
parallelism in the increasing Ki67 scores across the plots. In other
words, laboratories measuring higher or lower than others tended
to do so relatively consistently. In group 3 one lab (N) can be seen
to score considerably higher than the others in both the
unweighted and weighted scores particularly in the samples with
the higher scores. This laboratory also showed a number of higher
scores on the hot-spot method. Another laboratory in group 3 (T)
also showed substantially and consistently higher hot-spot scores
than the others, whereas in group 1 one laboratory (A) can be
seen to score consistently lower than the others.
Categorical concordance of Ki67 scoring
With regard to agreement on a categorical level (rather than on a
continuous, 0–100% scale), considering the categories o10%, 10–
20%, and420%, the relationship between percent agreement and
continuous score is shown in Supplementary Figure 3. It shows
excellent to perfect agreement on cases with scores that are either
much lower or higher than the intermediate range of 10–20%.
Visually, there was moderately strong agreement across
laboratories in the pathologist-selected location of the hot-spots
in each of the core-cut biopsies (Figure 5 shows some examples;
virtual slide images of all core-cut biopsy slides used in this study
and the corresponding selected fields and scores can be viewed at
http://www.gpec.ubc.ca/papers/ki67p3).
After selection of the fields to score, the median times required
for nuclei counting were 3 and 4 min for the global and hot-spot
methods, respectively.
DISCUSSION
The overarching goal of the International Ki67 Working Group
multiphase program is to build enough evidence to either support
or refute the notion that Ki67 assessed by immunohistochemistry
is sufficiently analytically and clinically validated to be implemen-
ted in routine clinical practice for management of breast cancer.10
Our previous studies demonstrated substantial interlaboratory
variability in Ki67 scoring among some of the world’s leaders in
the field, even when reading centrally stained slides (phase 1).17
However, this variability was reduced by introducing a standar-
dized, practical visual scoring method (phase 2)18—a method that
does not require any special equipment beyond a desktop
computer and light microscope.
In this third study, we progressed to a more ‘real world’
circumstance of reading Ki67 staining of core biopsies, while still
controlling for variability due to preanalytical and analytical aspects
of the assay.10 We have demonstrated that it is possible, given a set
of clearly defined training exercise and scoring instructions, for
pathologists to achieve high interobserver agreement in scoring
Ki67 on core-cut biopsies using a conventional light microscope
and manual field selection, with no additional aid such as counting
grid or software. The average time taken to score, once fields for
scoring had been selected, was between 3 and 4 min regardless of
the method and was judged to be acceptable in general practice by
the participants in the current study.
We found that the global unweighted method achieved the
observed highest ICC and CI (0.87, 95% CI: 0.81–0.93) compared
with weighted global (0.87, 95% CI: 0.7999–0.93) and hot-spot
Table 1. Summary of ICC values for different scoring methods
Different-section ICC Same-section ICC
Unweighted
global
0.87 (95% CI: 0.81–0.93) 0.88 (95% CI: 0.81–0.93)
Weighted global 0.87 (95% CI: 0.7999–0.93) 0.87 (95% CI: 0.80–0.93)
Hot-spot 0.84 (95% CI: 0.77–0.92) 0.84 (95% CI: 0.77–0.92)
Abbreviations: CI, credible interval; ICC, intraclass correlation coefficient.
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methods (0.84, 95% CI: 0.77–0.92). Thus the global method was
the only one to meet the prespecified criterion of success but the
other methods missed this criterion by a small amount and cannot
be ruled out as viable alternatives. The results do not provide
sufficient evidence that the global method is significantly more
reproducible, as measured by ICC, than the others. There
appeared to be moderately strong agreement in the location of
the selected hot-spots across laboratories (Figure 5a). However, as
shown in Figure 5b, even a very slight difference in hot-spot
location could result in a large difference in the Ki67 scores (8.6%
vs. 26%). Our findings are in agreement with other reports, in
which a marginally higher concordance among global compared
with hot-spot scores was observed (ICC = 0.904 vs. ICC = 0.894,
respectively).19 We propose that differences in individual fields
average out in the global method, and thus the overall score is
more robust to variability introduced by the exact localization of
the fields selected for scoring.
Despite the conclusion that the scoring aspect of analytical
validity has been achieved based on overall assessment by ICC,
there are still a few cases with large discrepancies (Figures 4a–c).
To understand potential sources of these variabilities, a subse-
quent exploratory examination of the field selections and scores
on individual fields were performed (Supplementary Document:
‘Exploratory examination of scoring fields’). Five sources of
variability were identified: (1) scoring of ductal carcinoma in situ
tissue; (2) scoring of stromal cells; (3) positive nuclei being
localized within a different part of the selected field; (4) need for
recalibration; (5) different hot-spots within a single slide exhibiting
Figure 1. Ki67 scores (a, unweighted global; b, weighted global; c, hot-spot) of all 22 laboratories (by group): black for Group 1, medium gray
for Group 2, and light gray for Group 3. Laboratories are ordered (within each group) by the median scores. The bottom/top of the box in each
box plot represent the first (Q1)/third (Q3) quartiles, the bold line inside the box represents the median and the two bars outside the box
represent the lowest/highest datum still within 1.5 × the interquartile range (Q3–Q1). Outliers are represented with empty circles.
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different Ki67 scores. Some of these factors may be correctable/
preventable (1, 2, 4) while others may be difficult to avoid (3, 5).
Among the rest of the cases, much of the scoring variability that
remains between laboratories relates to relatively consistent low
or high bias for scorers. Establishment of external quality
assessment schemes and regular participation in such programs
may improve the agreement between laboratories further,
especially in the area of standardizing staining protocol (which
has not yet been addressed in any of our studies).
Similar to what was observed in phase 2,18 clinically important
discrepancies persisted among laboratories for some cases in the
intermediate Ki67 range between 10 and 20% (Supplementary
Figure 4). These discrepancies are of concern, since this is the
range in which cutoffs to distinguish high from low Ki67 levels are
usually selected and used to make clinical decisions.6,13,20 There
were 19 cases for which at least one of the 22 laboratories
reported an unweighted global score in the range of 10%⩽ Ki67⩽
20%. Strikingly, there were no cases where all laboratories
provided scores that were confined to this range. If the
intermediate Ki67 range extends to 10%⩽ Ki67⩽ 30%, then there
were 26 cases for which at least one of the 22 laboratories
reported an unweighted global score in this range. There was only
one case for which all laboratories provided scores in this
extended cutoff range.
On the other hand, as evident from the heat maps (Figures 4a–
c), exceptionally high to unanimous agreement was observed for
cases with median Ki67 scores that were either much higher or
lower than the intermediate range (10%⩽ Ki67⩽ 20%): 100%
agreement was observed with the global method (unweighted
and weighted) on 11/30 (37%) cases and, with hot-spot method,
13/30 (43%) cases. Supplementary Figure 3 shows the relationship
between scores and the rate of agreement on categories. It
demonstrates that there is often some disagreement, but for
scores that are far away from the intermediate range, for example,
above 35%, everyone agreed. However, at lower levels there was
increasing disagreement.
Ki67 IHC might be used for one of many possible applications,
including for determination of breast cancer intrinsic subtype,21
use in IHC-based multiparameter assays to approximate results
from gene expression assays such as the 21-gene recurrence
score,14,15 and use in IHC-based prognostic models.22,23 Regard-
less, Ki67 is usually interpreted in the context of other
clinicopathological parameters, such as tumor size, lymph node
status and grade, or biomarkers, such as ER, PR and HER2 status. In
this regard, Denkert et al. noted that treatment decisions for
individual patients should not be made based on small differences
of Ki67 around a given cutpoint.16 Further studies in the impact of
Ki67 scoring variability on multiparameter clinical application
would be beneficial. Regardless, the increasing scoring concor-
dance we have observed through our three phases of consensus
training suggests some progress toward Ki67 immunohistochem-
istry applicability in the standard of care setting, assuming proper
training and adherence to proficiency testing.
While our study shows that Ki67 visual scoring systems
can be standardized to reach high levels of interobserver
agreement (as measured by ICC) in centrally stained core-cut
biopsy samples, it has several limitations. In clinical practice,
additional preanalytical and analytical aspects, such as staining
protocol differences,10 will add substantial variability, as will
moving from core-cut biopsies onto whole sections. In addition,
the clinical validity (and therefore clinical utility) of this specific
scoring system has yet to be confirmed. The data from the current
phase 3 study are sufficiently positive to support proceeding to
evaluation of these other aspects by consortium members in a
series of planned studies.
In conclusion, we believe we are one step closer to standardizing
the Ki67 immunohistochemistry assay for use in breast cancer.
However, at this stage, we cannot yet recommend this assay
platform to be used to drive patient-care decisions in clinical practice.
MATERIALS AND METHODS
This study was approved by the British Columbia Cancer Agency Clinical
Research Ethics Board (protocol H10-03420). All samples used in this study
were donated by patients who signed a generic consent. All core-cut
biopsy material used in this study was excess to diagnostic requirements
and ethically available for quality control studies.
Case selection
One hundred and ten cases of estrogen receptor (ER) positive breast cancer
were selected from the Academic Department of Biochemistry (ADB) tumor
bank at the Royal Marsden Hospital, UK. Sixty-nine of these were further
selected for initial sectioning, based on visual estimation of the available
material, Haematoxylin and Eosin (H&E) and Ki67 staining using Academic
Biochemistry protocols.24 Quality of each section (for example, crush artifacts
and cellularity) was assessed and the percentage of Ki67 positivity was
estimated. A set of 40 core-cut biopsy blocks was sectioned and stained in
the Royal Marsden Hospital Histopathology Department using monoclonal
antibody MIB1 at dilution 1:50 (DAKO UK, Cambridgeshire, UK) using an
automated staining system (Ventana Medical Systems, Tucson, AZ, USA)
according to the criteria established by consensus of the International Ki67
Working Group.10 The final set of 30 core-cut biopsy sections was selected
on the basis of sufficient cell numbers and quality of staining
(Supplementary Figure 1). The distribution of clinicopathological parameters
among these 30 cases is shown in Supplementary Table 1.
Sample preparation and distribution
Twenty-four volunteer laboratories, most of whom participated in
phase 1 or 2 of the International Ki67 Working Group initiatives,
representing 23 institutions from 11 countries, were invited to participate
in phase 3.
Five adjacent sections from each of the 30 core-cut biopsy source blocks
were centrally stained. The first section was stained with H&E, the second
with a myoepithelial marker (p63) and the third to fifth sections with Ki67.
Because the time required to have all laboratories review the same slide
would have been prohibitive, the latter three Ki67-stained sections were
prepared and are designated Groups 1, 2, and 3. Each group of slides
included 30 sections, one from each of the 30 patients. The participating
laboratories were initially divided into three groups (eight laboratories in
each group) and members within the same group were given the same
group of slides to score. Because the slides were damaged en route to the
third volunteer laboratory in Group 2, members within this group who had
not yet scored were subsequently reassigned to Group 1 or 3. Two
biological residual laboratory section
unweighted global score
weighted global score
hot-spot score
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Figure 2. Variance component analysis. Variation due to different
components are presented in a bar plot to show the relative
magnitude differences between them. Numeric values of the variance
components estimates and the corresponding credible intervals are
shown in Supplementary Table 5.
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volunteer laboratories did not complete the study in time for the analysis.
Twenty-two laboratories successfully completed the study: 10 laboratories
in Group 1, two in Group 2 and 10 in Group 3.
Scoring protocol
All laboratories were required to complete the phase 2 web-based
calibration exercise18 prior to the phase 3 scoring. This calibrator is publicly
accessible at http://www.gpec.ubc.ca/calibrator. The detailed scoring
protocol is found in Supplementary Document: ‘Instructions for Ki67
Reproducibility Study Phase 3: Core Biopsies’. A modified version of the
scoring software (modified for offline use) used in this study can be
downloaded at: http://www.gpec.ubc.ca/papers/ki67p3.
Scoring methods
Three scoring methods were assessed in this study: (1) an unweighted
global assessment of Ki67 staining; (2) a global assessment that is
weighted according to the estimated percentage of the total cancer area
covered by each of high, medium, low, or negligible Ki67 staining levels
and (3) assessment of Ki67 only in ‘hot-spots.’
Global methods attempt to derive an average score across all the
tissue available for assessment. In the weighted and unweighted global
methods, Ki67 index counting was performed in the same manner, but the
final Ki67 score was derived differently. Adapted from a scoring protocol
that has been used routinely in the Dowsett ADB laboratory,24 these two
global methods require the pathologist to first assess staining hetero-
geneity by estimating the percentages of the invasive tumor component
of the slide exhibiting relatively high, medium, low or negligible Ki67
scores. On the basis of these estimates, a standard algorithm
(Supplementary Figure 2) determined the required number of fields to
score for each Ki67 score level (total up to four fields). The pathologist was
then asked to count up to 100 invasive tumor nuclei within each field,
using a ‘typewriter’ pattern, similar to how a tissue microarray core was
scored in the phase 2 study.18
Variations on hot-spot assessments are often used by pathologists
for mitotic counting, where the pathologist identifies what appears
GROUP 1 GROUP 3
Specimen number Specimen number 
Figure 3. Variability in Ki67 scores (a, c and e correspond to Group 1; b, d and f correspond to Group 3). Each line represents Ki67 scores from
one laboratory. Shaded region indicates Ki67 scores between 10 and 20%. Scores from Group 2 are not shown since there are only two
laboratories in this group.
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to be the most active area of cell division. The hot-spot method
required the pathologist to select one high-power field with high
staining rate and count up to 500 invasive tumor nuclei in a ‘typewriter’
pattern.
Statistical analyses
Prespecified criterion for success. Prior to data collection, it was
hypothesized that at least one of the scoring methods would have an
associated ICC of at least 0.80. For planning purposes, power calculations
Figure 4. Heat map of Ki67 scores (a: unweighted global; b: weighted global; c: hot-spot). Rows represent cases and columns represent
laboratories. Green color indicate that the score is o10%, yellow 10–20%, and red 420%. Cases are ordered by the median scores (across
laboratories), which are shown in parentheses beside the specimen number. Laboratories are ordered (within each group) by the median
scores (across cases). The three colon-separated numbers to the right of the table represent the number of laboratories giving scores falling
into different ranges: o10% (left-most), 10–20% (middle) and 420% (right-most). For example, ‘15:6:1’ indicates that 15 laboratories gave a
score of o10%, six laboratories between 10 and 20% and one laboratory 420%.
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performed under a variety of scenarios considered to represent good
reproducibility and similar to the results observed in the phase 2 study
showed that with 21 laboratories there would be 80% power to exclude
ICCs lower than the prespecified ICC of 0.8 from a 95% credible interval for
a given scoring method. This success criterion of ‘0.8’ was chosen using
criteria similar to those for Kappa value interpretation: 0.81–1 indicating
‘almost perfect’ agreement.25
Ki67 scoring. The Ki67 score was defined as the percentage of invasive
tumor cells positively stained in the examined field(s). Positive staining was
defined as any brown stain in the nucleus above background, illustrated by
sample images; negative staining was scored when the invasive cancer cell
showed only a blue counterstained nucleus. The unweighted global and
hot-spot scores were simply the total number of positively stained tumor
nuclei counted divided by the total number of tumor nuclei counted (in
Figure 4. (Continued)
Figure 5. Hot-spot field selection by different laboratories on the same core-cut biopsy slide. (a) Selections (indicated by red circles) on some
example core biopsies. (b) Example of a single-core biopsy (median score: 12%) with zoomed-in fields. Each laboratory was asked to circle the
area considered by that laboratory to be the hot-spot (b-i). Most pathologists honed in on the same area of the core, although individual-
selected circular scoring fields do not always overlap. (b-iii, b-iv) Segments of the same area chosen by two different laboratories to read Ki67.
(b-v) The ‘outlier’ field selected by only one laboratory as the hot-spot.
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the one hot-spot field, or across all fields for the global method). The
weighted global score was derived with tumor nuclei counts in each
assessed field weighted by the estimated percentage of the total cancer
area covered by each of high, medium, low, or negligible Ki67 staining
levels. For example, consider a slide estimated to have 10% of its area
covered by relatively high Ki67 index regions, while 90% of the area is
covered by relatively low-level Ki67 regions. By the algorithm
(Supplementary Figure 2), the required number of fields to select and
score is one high field and three low fields. Suppose the number of
positive/total tumor nuclei counted in the high field is 85/100 and the
three low fields are 30/100, 20/80, and 18/90. The weighted Ki67 score
would be 0.1 × (85/100)+0.9 × ((30+20+18)/(100+80+90)) = 31%, whereas
the unweighted score would be (85+30+20+18)/(100+100+80+90) = 41%.
For the statistical analysis, the Ki67 score was transformed to a logarithmic
scale by adding 0.1% and applying a log base 2 transformation to satisfy
model assumptions of normality and constant variance.10
ICC estimates (ranging from 0 to 1, with 1 representing perfect
reproducibility) were computed as previously reported in the phase 2
study.18 Briefly, variance component analyses were performed to quantify
the contributions from the following sources of variability: scoring
laboratory, patient tumor (biological variation—each core-cut biopsy
block represents a unique patient) and section of the core-cut biopsy block.
Similar to the phase 2 study, same-section and different-section ICC were
computed. Same-section refers to scoring laboratories scoring the same set
of core-cut biopsy slides, whereas different-section refers to scoring
laboratories scoring different sections of the same core-cut biopsy blocks.
CI for the variance components and the ICCs were obtained using the
Markov Chain Monte Carlo routines for fitting generalized linear mixed
models.
All data analyses were performed using R version 3.2.1.26 Sources of
variation in log2-transformed Ki67 scores were analyzed using random
effects models as implemented in the R packages lme4 and MCMCglmm.
Data were visualized using heat maps, boxplots and spaghetti plots.
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